Weekly News

Home » Weekly News

Weekly news updates are currently posted on the Internet site and sent out via
e-blast to provide up-to-date information on what has been covered in the news regarding lung cancer in the previous week.

Would you like to receive our newsletter directly to your inbox?

Lung Cancer News
Week Ending October 21, 2019

Phase III CANOPY Studies to Investigate Canakinumab in NSCLC
“Three phase III studies are set to investigate the value of canakinumab, a monoclonal antibody, in the treatment of non-small-cell lung cancer (NSCLC), according to abstracts presented at the International Association for the Study of Lung Cancer (IASLC) 2019 North America Conference on Lung Cancer.”

Long-term Asbestos Exposure Can Trigger Lung Cancer in Children, Say Experts
“Asbestos is a group of naturally occurring fibrous minerals that have the potential to cause cancer, according to the World Health Organization (WHO) and other health groups.”

Durvalumab Combination Improves Outcomes in Patients With ES-SCLC
“At the 2019 ESMO Congress, updated data from the phase III CASPIAN trial demonstrated delays in the development of new lesions and improvements in patient-reported outcomes (PROs) with the addition of durvalumab (Imfinzi), a PD-L1 inhibitor, to etoposide and platinum-based chemotherapy in the frontline for patients with extensive-stage small cell lung cancer (ES-SCLC).1 However, PD-L1 expression did not appear predictive of response.”

Predicting The Benefits Of Immunotherapy in NSCLC
“Ongoing research is examining how the biomarkers PD-L1 and tumor mutational burden (TMB) can be used in a complementary fashion to predict which patients with advanced non–small cell lung cancer (NSCLC) will benefit most from immunotherapy.”

Current and ex smokers may lower lung cancer risk with exercise
“(Reuters Health) – Men who are current or former smokers may be less likely to develop or die from lung cancer when they’re more physically fit, a recent study suggests.”

E-cigarette smoke associated with lung cancer, inflammation, as federal agencies respond to vaping deaths
“E-cigarette smoke, like tobacco smoke, may, in fact, cause cancer, new studies suggest.”

Challenges of Molecular and Immune Testing in Lung Cancer, and Implications of Liquid Biopsies
“New York—At the 2019 Perspectives in Thoracic Oncology meeting, Marc Ladanyi, MD, Chief of Molecular Diagnostics at Memorial Sloan Kettering Cancer Center (MSKCC), New York, spoke with Oncology Learning Network about the challenges of molecular and immune testing in lung cancer, and the implications of liquid biopsies in therapeutic management.”

ESMO 2019: Dr. Spigel Highlights Progress in Lung Cancer